Hexarelin switches on a receptor in your brain and pituitary that triggers a short, natural burst of growth hormone. Your body normally releases that hormone in pulses, mostly during deep sleep. Hexarelin sits in the broader growth hormone peptide family, alongside options like CJC-1295, though it works through its own receptor.
It binds the same receptor ghrelin uses and pushes the pituitary to fire one of those pulses on command. More growth hormone in the blood prompts the liver to make more IGF-1, the messenger behind much of the body’s tissue repair and fat metabolism. Hexarelin is one of the stronger options in its class, more stable and more potent than older peptides like GHRP-6, and it survives the gut so poorly, with oral availability under 1%, that it’s studied as an injection, not a pill.
It depends on the dose, the source, and whether a clinician is watching. Used blind, no. Hexarelin doesn’t only touch growth hormone.
The same receptor that releases growth hormone also nudges the stress system. Research in healthy volunteers found hexarelin raised cortisol and ACTH, the body’s stress hormones, and it can lift prolactin as well. Water retention, tingling, and a bump in appetite show up too. Gentler peptides like Sermorelin tend to carry a lighter side-effect load, which is part of why some patients start there. None of this lands on a before-and-after reel. It lands in blood work and in how you feel a few months in.
So, what is hexarelin peptide? A potent research compound that can move growth hormone, with real open questions and a gray market eager to sell it to you. The peptide was never the hard part. The source, the plan, and the person holding the syringe are. If you’re curious about hexarelin peptide, do it with a clinician who’ll tell you the truth, including when the truth is no.
References:
Broglio, F., Guarracino, F., Benso, A., Gottero, C., Prodam, F., Granata, R., Avogadri, E., Muccioli, G., Deghenghi, R., & Ghigo, E. (2002). Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. European Journal of Pharmacology, 448(2–3), 193–200. https://pubmed.ncbi.nlm.nih.gov/12144941/
Locatelli, V., Rossoni, G., Schweiger, F., Torsello, A., De Gennaro Colonna, V., Bernareggi, M., Deghenghi, R., Müller, E. E., & Berti, F. (1999). Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology, 140(9), 4024–4031. https://pubmed.ncbi.nlm.nih.gov/10465272/
McDonald, H., Peart, J., Kurniawan, N., Galloway, G., Royce, S., Samuel, C. S., & Chen, C. (2018). Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiological Reports, 6(9), e13699. https://pubmed.ncbi.nlm.nih.gov/29756411/
Xu, X., Ding, F., Pang, J., Gao, X., Xu, R. K., Hao, W., Cao, J. M., & Chen, C. (2012). Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. American Journal of Physiology-Heart and Circulatory Physiology, 303(6), H703–H711. https://pubmed.ncbi.nlm.nih.gov/22842067/
Zhao, H., Liu, G., & Wang, T. (2014). The cardiovascular action of hexarelin. Acta Biochimica et Biophysica Sinica, 46(10), 902–907. https://pmc.ncbi.nlm.nih.gov/articles/PMC4178518/